The QTGAL Knockout HeLa Polyclonal Cells are a CRISPR/Cas9-edited polyclonal knockout cell population derived from the HeLa human cervical adenocarcinoma epithelial cell line. This product provides a genetically heterogeneous knockout model in which the QTGAL gene has been disrupted via CRISPR/Cas9-mediated gene disruption, yielding a loss-of-function population suitable for studying galactosyltransferase-dependent processes. As a polyclonal pool, the cells collectively represent a range of editing outcomes, avoiding the clonal artifacts associated with single-cell-derived lines while providing reduced QTGAL function across the population.
HeLa cells are an immortalized epithelial cell line originally derived from a cervical adenocarcinoma. They serve as a robust, well-characterized platform for cancer biology, signal transduction, and glycobiology research. HeLa cells express active glycosylation machinery and key glycoproteins involved in adhesion and signaling, making them a relevant host for investigating the functional consequences of QTGAL disruption. Their extensively documented genomic and proteomic landscape supports reproducible experimental analyses in a disease-relevant context.
QTGAL encodes a Golgi-resident galactosyltransferase that transfers galactose from UDP-galactose to acceptor glycoproteins and glycolipids, participating in N-glycan and O-glycan biosynthesis and glycosphingolipid metabolism. QTGAL activity is modulated by upstream signals including epidermal growth factor receptor (EGFR) signaling, endoplasmic reticulum (ER) stress, and Src kinase. Its function directly influences the glycosylation of downstream targets such as MUC1, integrins, and E-cadherin. The enzyme interacts with the conserved oligomeric Golgi (COG) complex, GOLPH3, and nucleotide sugar transporters, which coordinate proper glycan assembly. Consequently, QTGAL disruption perturbs glycosylation-dependent protein maturation, impacting cell adhesion, migration, and signaling.
In the HeLa adenocarcinoma background, QTGAL knockout is particularly useful for examining the role of aberrant glycosylation in tumor progression. HeLa cells exhibit altered glycan structures that contribute to malignant phenotypes including enhanced proliferation, immune evasion, and metastasis. Eliminating QTGAL function allows researchers to assess how galactosylation defects affect glycoconjugate-dependent processes, such as adhesion molecule stability and receptor signaling. This model provides insight into congenital disorders of glycosylation, tumor metastasis, and immune dysregulation, where glycosylation changes are critical modulators of disease pathology.
The QTGAL Knockout HeLa Polyclonal Cells are well suited for glycobiology and cancer research applications. Typical assays include lectin blotting and lectin-based flow cytometry to profile galactose-containing glycans, mass spectrometry glycomics for detailed structural analysis, and adhesion assays to evaluate cell?Ccell and cell?Cmatrix interactions. These cells can also support glycoengineering to modulate glycoprotein properties and biomarker discovery targeting glycosylation signatures. For additional technical details and ordering information, please contact Ascent Research.
